Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs PT 20 (Primary)
- Indications Hypophosphataemia
- Focus Registrational; Therapeutic Use
- Acronyms PEACH
- Sponsors Phosphate Therapeutics
- 07 May 2015 Primary endpoint has been met (To assess the effect of oral PT20 over placebo on serum phosphate) according to a Phosphate Therapeutics media release.
- 07 May 2015 Results published in the Phosphate Therapeutics Media Release.
- 29 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History